ProBioGen and LAVA Therapeutics sign cell line development agreement

The agreement marks the second cell line development collaboration between the two companies

CDMO ProBioGen has agreed to support LAVA Therapeutics by conducting cell line development of the biotech firm's novel bispecific gamma-delta T cell engager (TCE) candidate.

The extended partnership will see the CDMO use its CHO.RIGHT expression platform, including its DirectedLuck Transposase technology for the generation of stable higher-titer cell lines.

According to Stephen Hurly, Chief Executive Officer and President of LAVA Therapeutics, the collaboration is based on the "great results" from a previous agreement with the specialist in developing and manufacturing complex therapeutic proteins.

In a statement, ProBioGen's Chief Executive Officer, Dr Lutz Hilbrich, described the company's cell line development platform as "perfectly suited" for novel protein formats, yielding biologics with optimised properties.

LAVA Therapeutics' lead program, LAVA-051, is expected to enter a Phase 1/2a clinical study in hematologic malignancies in the first half of 2021.

Related categories

Biopharmaceuticals CHO and cell lines

Related News

News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma

The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024.

30 Jan 2024
News Women in Pharma: Minding the Gap at Pharmapack 2024

2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused...

29 Jan 2024
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation

The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles.

24 Jan 2024
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures

The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year.

9 Jan 2024
News New Novo Nordisk AI hub for drug discovery to open in London, UK

Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations.

5 Jan 2024
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025

German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa.

20 Dec 2023
News Women in Pharma: Looking back on 2023 and moving forward to 2024

In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond.

19 Dec 2023
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations

During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.

18 Dec 2023